Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-03-19
2010-10-12
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500
Reexamination Certificate
active
07812002
ABSTRACT:
The invention provides novel double stranded oligoribonucleotides that inhibit the Nrf2 gene. The invention also provides a pharmaceutical composition comprising one or more such oligoribonucleotides, and a vector capable of expressing the oligoribonucleotide. The present invention also relates to methods and compositions for treating or preventing the incidence or severity of a cancerous disease, particularly various lung cancers.
REFERENCES:
patent: 5898031 (1999-04-01), Crooke
patent: 6107094 (2000-08-01), Crooke
patent: 6506559 (2003-01-01), Fire et al.
patent: 7452987 (2008-11-01), Giese et al.
patent: 2002/0164576 (2002-11-01), Pedersen et al.
patent: 2004/0005579 (2004-01-01), Birse et al.
patent: 2004/0219569 (2004-11-01), Yehiely et al.
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2006/0069056 (2006-03-01), Feinstein
patent: 2006/0217329 (2006-09-01), Feinstein
patent: 2006/0217331 (2006-09-01), Vargeese et al.
patent: 2006/0292586 (2006-12-01), Schroth et al.
patent: 2006/0293511 (2006-12-01), Dellinger
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: 2007/0042418 (2007-02-01), Yehiely et al.
patent: 2007/0098728 (2007-05-01), Pedersen et al.
patent: 2007/0185047 (2007-08-01), Bhat et al.
patent: 2008/0064650 (2008-03-01), Feinstein et al.
patent: 2008/0108583 (2008-05-01), Feinstein
patent: WO 00/44895 (2000-08-01), None
patent: WO 01/36646 (2001-05-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO-01/94629 (2001-12-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 02/055693 (2002-07-01), None
patent: WO 03/070918 (2003-09-01), None
patent: WO 03/074654 (2003-09-01), None
patent: WO 2004/015107 (2004-02-01), None
patent: WO 2006/128041 (2006-11-01), None
patent: WO 2006/128041 (2006-11-01), None
patent: WO 2006/129881 (2006-12-01), None
patent: WO 2008/124660 (2008-10-01), None
Barik Mol. Med 2005, 83: 764-773.
Bartel DP. Cell. Jan. 23, 2004; 116(2): 281-97MicroRNAs: genomics, biogenesis.
Bitko et al., Nat. Med. 2005, 11(1):50-55.
Caplen et al.Proc Natl Acad Sci 2001, 98:9742-9747).
Chakraborty—Current Drug Targets 2007 8(3):469-82.
Chalk AM, Wahlestedt C, Sonnhammer EL. 2004 Improved and automated prediction of effective siRNA Biochem. Biophys. Res. Commun. Jun. 18; 319(1): 264-74:.
Elbashir et al. 2001, Genes Dev., 15, 188).
Elbashir etal. Nature 2001, 411:494-498.
Fire et al., 1998, Nature 391, 806.
Lee et al., Nature, 2003, 425:415-9.
Levenkova N, Gu Q, Rux JJ. 2004, Gene specific siRNA selector Bioinformatics. I 12; 20(3): 430-2.
McManus & Sharp, Nature Rev Genet, 2002, v.3, p. 737-47.
Singh et al., Camcer Res. 2008: 68(19) RNAi-Mediated Silencing of Nuclear Factor Erythroid-2-Related Factor 2 Gene Expression in Non-Small Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy.
Sioud M, Leirdal M., 2004, Potential design rules and enzymatic synthesis of siRNAs,Methods Mol Biol.; 252:457-69.
Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A, Ueda R, Saigo K., Guidelines for the selection of highly effective siRNA sequences for mammalian and chik RNA interference Nucleic Acids Res. 2004 I 9;32(3);936-48.
Yehiely et al., U.S. Appl. No. 09/499,553, and claims pending at time of abandonment.
Kotlo et al., (2003). “Nrf2 is an inhibitor of the Faspathway as identified by Achilles' Heel Method, a new function-based approach to a gene identification in human cells,”Oncogene, 22: pp. 797-806.
International Search Report issued by the International Searching Authority (ISA/US) on Jan. 8, 2009 in connection with International Application No. PCT/IL08/00391.
Written Opinion issued by the International Searching Authority (ISA/US) on Jan. 8, 2009 in connection with International Application No. PCT/IL08/00391.
International Preliminary Report on Patentability issued by the International Searching Authority (ISA/US) on Jan. 28, 2010 in connection with International Application No. PCT/IL08/00391.
Gong et al. (2006), “Nrf2 is increased by CYP2E1 in Rodent Liver and HepG2 Cells and Protects Against Oxidative Stress Caused by CYP2E1”.Hepatology,43:144-153.
AB162435,Bos taurusnrf2 mRNA for NF-E2-related factore-2, complete cds. Dec. 21, 2004 [retrieved from the Internet May 6, 2010; http://www.ncbi.nlm.nih.gov
uccore/56744173].
International Search Report issued by the International Searching Authority (ISA/US) on Apr. 2, 2010 in connection with International Application No. PCT/IL09/00387.
Written Opinion issued by the International Searching Authority (ISA/US) on Apr. 2, 2010 in connection with International Application No. PCT/IL09/00387.
Cooper & Dunham LLP
Gibbs Terra Cotta
McGarry Sean
Quark Pharmaceuticals Inc.
White John P.
LandOfFree
Oligoribonucleotide inhibitors of NRF2 and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligoribonucleotide inhibitors of NRF2 and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligoribonucleotide inhibitors of NRF2 and methods of use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4216247